Literature DB >> 2460228

Enhanced expression of c-myc and epidermal growth factor receptor (C-erbB-1) genes in primary human renal cancer.

M Yao1, T Shuin, H Misaki, Y Kubota.   

Abstract

We have analyzed the expression of 12 protooncogenes, c-Ha-ras, c-Ki-ras, N-ras, c-myc, N-myc, c-fos, c-abl, c-fes, c-fms, c-raf, c-erbB-1, and c-erbB-2, in tissues of human renal cell carcinomas and in adjacent normal kidneys. Comparative densitometry of Northern blot analyses demonstrated enhanced level of c-myc gene expression, i.e., greater than threefold increase over normal kidney tissues, in 11 of 15 (73%) of the tumors examined. Increased levels of c-erbB-1 mRNA were likewise observed in seven of 15 (47%). Interestingly, many of the tumors exhibiting elevated levels of c-erbB-1 revealed increases in c-myc mRNA levels. However, Southern blot analysis failed to detect gene amplification or rearrangement in the tumors with elevated levels of c-myc and/or c-erbB-1. Although N-ras, c-fos, and c-raf gene transcripts were detected in both malignant and normal tissues, differences in these protooncogene expressions were not found between the carcinomas and normal kidneys. Significant elevations of expression were found in one of 16 cases of each for c-Ha-ras and c-fms, whereas expression of c-Ki-ras, N-myc, c-fes, c-abl, or c-erbB-2 could not be detected in any of the tissues surveyed. These results suggest that activation of c-myc and c-erbB-1 genes may be involved in the development of human renal cell carcinomas.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 2460228

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  30 in total

1.  The von Hippel-Lindau tumor suppressor gene product interacts with Sp1 to repress vascular endothelial growth factor promoter activity.

Authors:  D Mukhopadhyay; B Knebelmann; H T Cohen; S Ananth; V P Sukhatme
Journal:  Mol Cell Biol       Date:  1997-09       Impact factor: 4.272

Review 2.  Dermatologic adverse events to targeted therapies in lower GI cancers: clinical presentation and management.

Authors:  Viswanath Reddy Belum; Andrea Cercek; Virginia Sanz-Motilva; Mario E Lacouture
Journal:  Curr Treat Options Oncol       Date:  2013-09

3.  Induction of renal adenocarcinoma by a nonmutated erbB oncogene.

Authors:  C A Taglienti-Sian; B Banner; R J Davis; H L Robinson
Journal:  J Virol       Date:  1993-02       Impact factor: 5.103

4.  Identification and classification of differentially expressed genes in renal cell carcinoma by expression profiling on a global human 31,500-element cDNA array.

Authors:  J M Boer; W K Huber; H Sültmann; F Wilmer; A von Heydebreck; S Haas; B Korn; B Gunawan; A Vente; L Füzesi; M Vingron; A Poustka
Journal:  Genome Res       Date:  2001-11       Impact factor: 9.043

5.  Renal Cell Carcinomas in Vinylidene Chloride-exposed Male B6C3F1 Mice Are Characterized by Oxidative Stress and TP53 Pathway Dysregulation.

Authors:  Schantel A Hayes; Arun R Pandiri; Thai-vu T Ton; Hue-Hua L Hong; Natasha P Clayton; Keith R Shockley; Shyamal D Peddada; Kevin Gerrish; Michael Wyde; Robert C Sills; Mark J Hoenerhoff
Journal:  Toxicol Pathol       Date:  2015-12-17       Impact factor: 1.902

6.  High-throughput tissue microarray analysis to evaluate genes uncovered by cDNA microarray screening in renal cell carcinoma.

Authors:  H Moch; P Schraml; L Bubendorf; M Mirlacher; J Kononen; T Gasser; M J Mihatsch; O P Kallioniemi; G Sauter
Journal:  Am J Pathol       Date:  1999-04       Impact factor: 4.307

7.  Differential responses of human tumor cell lines to anti-p185HER2 monoclonal antibodies.

Authors:  G D Lewis; I Figari; B Fendly; W L Wong; P Carter; C Gorman; H M Shepard
Journal:  Cancer Immunol Immunother       Date:  1993-09       Impact factor: 6.968

8.  Dual roles for coactivator activator and its counterbalancing isoform coactivator modulator in human kidney cell tumorigenesis.

Authors:  Yun Kyoung Kang; Rachel Schiff; Lan Ko; Tao Wang; Sophia Y Tsai; Ming-Jer Tsai; Bert W O'Malley
Journal:  Cancer Res       Date:  2008-10-01       Impact factor: 12.701

9.  Differential expression in clear cell renal cell carcinoma identified by gene expression profiling.

Authors:  Brian R Lane; Jianbo Li; Ming Zhou; Denise Babineau; Pieter Faber; Andrew C Novick; Bryan R G Williams
Journal:  J Urol       Date:  2008-12-17       Impact factor: 7.450

10.  Genetic alterations of HER genes in chromophobe renal cell carcinoma.

Authors:  Wen Hui Weng; Ying Tzu Chen; Kai Jie Yu; Ying Hsu Chang; Cheng Keng Chuang; See Tong Pang
Journal:  Oncol Lett       Date:  2016-02-08       Impact factor: 2.967

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.